Latest news for Weed Growth Fund (OTC:WEDG) Stock

Weed Growth Fund Inc is engaged in the investment, acquisition, operation, and management of, intellectual property and business ventures in hemp, medicinal cannabis, legalized cannabis, and related industries.

News

Penny Stocks

SEDG

WEDG

SolarEdge Technologies (NASDAQ: WEDG) shares are trading lower by roughly 1.16% to $180.52 Monday afternoon. The stock is lower by 24% over the trailing five sessions after the company came out with weak third-quarter guidance.

What Happened With Earnings Last Week?

What&#39;s Going On With SolarEdge Stock?

WEED GROWTH FUND INC by Weed Growth Fund, Inc.

Weed Growth Fund Inc

WEDGEMOUNT RES CORP by Wedgemount Resources Corp.

Wedgemount Resources Corp

Deutsche Bank analyst Edison Yu reinstates Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) with a Hold and announces $12 price target.

Price Target

Initiation

Analyst Ratings

Deutsche Bank Reinstates Hold on Dana, Announces $12 Price Target

Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases,&nbsp;announced its presentations&nbsp;at the European Respiratory Society (ERS) International Congress 2024 taking place in Vienna, Austria September 7 - 11, 2024. &nbsp;

Biotech

General

PLRX

Pliant Therapeutics Presents Data From Its Bexotegrast Program At The European Respiratory Society International Congress 2024

Monday, AstraZeneca&nbsp;Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with at least <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40779283/datopotamab-deruxtecan-showed-median-overall-survival-of-14-6-months-in-patients-with-advanced-non" rel="noreferrer noopener">one prior line of therapy</a>.
Detailed results showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxel.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40737381/astrazeneca-in-trouble-for-employee-detentions-in-china-over-illegal-activities" rel="noreferrer noopener">AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities</a>.
Dato-DXd is an engineered TROP2-directed DXd antibody-drug conjugate discovered by Daiichi Sankyo Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSKYF#OTC">DSKYF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) and being jointly developed by AstraZeneca and Daiichi Sankyo.
In the overall trial population, OS results numerically favored datopotamab deruxtecan compared to docetaxel (12.9 vs. 11.8 months) but did not reach statistical significance (hazard ratio [HR] 0.94; p=0.530).
In the prespecified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a 2.3-month improvement in OS compared to docetaxel (14.6 vs. 12.3 months).
The safety profile of datopotamab deruxtecan in TROPION-Lung01 was consistent with the previous analysis, including lower rates of dose reduction (20%, 30%) and discontinuation (8%, 12%) due to adverse events compared to docetaxel.
At the World Conference on Lung Cancer (WCLC), the British pharma giant shared results from the NeoCOAST-2 Phase 2 platform trial of Imfinzi&nbsp;(durvalumab) in multiple combinations, before and after surgery, in patients with early-stage (Stage IIA–IIIB) resectable NSCLC.
Preliminary results from the trial arm testing neoadjuvant Imfinzi plus datopotamab deruxtecan and carboplatin demonstrated a pathological complete response rate of 34.1% and a major pathological response rate of 65.9%.
Recently, the FDA approved&nbsp;AstraZeneca&#8217;s Imfinzi&nbsp;(durvalumab) in combination with chemotherapy for adult patients with resectable early-stage NSCLC and no known epidermal growth factor receptor mutations or anaplastic&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40416174/fda-approves-astrazenecas-blockbuster-cancer-drug-imfinzi-in-combination-with-chemo-for-non-small" rel="noreferrer noopener">lymphoma kinase rearrangements</a>.
Price Action: AZN stock is down 1.16% at $79.95 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40779934/fulcrum-therapeutics-upgraded-bofa-debates-pivotal-study-success-for-losmapimod-in-" target="_blank" rel="noreferrer noopener">Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease</a>.</li>
</ul>
Image by Robert Way via Shutterstock

Health Care

DSKYF

DSNKY

AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial

Dr. Reddy's Issues Clarification Regarding Allegations Tied To Engagement With Agora Advisory; Confirms Engagement Of Dhaval Buch From October 2020 To April 2021, Prior To Madhabi Buch's SEBI Chairpersonship; Asserts Compliance With Laws And Denies Any Preferential Treatment By SEBI

Deutsche Bank analyst Edison Yu reinstates Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Hold and announces $132 price target.

Deutsche Bank Reinstates Hold on Lear, Announces $132 Price Target

Aspira Women's Health Inc. ("Aspira") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of a paper in the journal Gynecologic Oncology highlighting data demonstrating that a multimodal assay combining miRNA with protein biomarkers, age, and menopausal status offered the most accurate classification of patients with an adnexal mass for the identification of early-stage ovarian cancer.

Aspira Women's Health Announces Publication Of Data Demonstrating Performance Of Its In-Development Blood Test For The Assessment Of Malignancy Risk In Patients With An Adnexal Mass

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk on Monday said that the EV giant will alter parking assistance features on the Cybertruck to ensure that the steering yoke does not move while the vehicle <a href="https://www.benzinga.com/news/24/09/40723263/senior-tesla-exec-says-cybertruck-may-get-parking-assistance-features-over-weekend-after-the-stainle">navigates itself into a parking spot.</a>
What Happened: &#8220;We should change that so the yoke is stationary, as it is not mechanically coupled to the wheels. The same goes for when it is on Autopilot,&#8221; Musk wrote on X, formerly Twitter, in response to a video by a Tesla enthusiast showing the Cybertruck yoke steering by itself as it seeks to park without human intervention.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We should change that so the yoke is stationary, as it is not mechanically coupled to the wheels. Same goes for when it is on Autopilot.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1833031094167572855?ref_src=twsrc%5Etfw">September 9, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cybertruck employs a steer-by-wire technology, meaning there is no mechanical connection between the steering wheel and the wheels. The sensors in the steering column instead communicate electronically with the steering racks. 
However, the enthusiast has questioned how the yoke will reset to the right position if it does not move with the wheels if the driver decides to intervene in the vehicle&#8217;s automated process. Musk is yet to clarify the same.
Why It Matters: The Cybetruck was recently equipped with <a href="https://www.benzinga.com/news/24/09/40723263/senior-tesla-exec-says-cybertruck-may-get-parking-assistance-features-over-weekend-after-the-stainle">parking assistance features</a>. The vehicle is yet to be equipped with Tesla&#8217;s Full Self-Driving technology, or FSD.
FSD is the most advanced version of Tesla&#8217;s driver assistance features termed autopilot.
The names, however, are a misnomer as the features do not make the vehicle autonomous or capable of self-driving but require active driver supervision. However, FSD allows for auto lane change, navigating interchanges, and more.
FSD release for the Cybertruck is <a href="https://www.benzinga.com/news/24/08/40499576/tesla-delays-elon-musks-timeline-yet-again-for-cybertruck-fsd-rollout-this-time-to-september">slated for Septembe</a>r, Tesla&#8217;s senior executive Ashok Elluswamy said late last month. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40789404/volkswagen-recalls-every-id-4-suv-in-u-s-for-door-malfunction-concerns">Volkswagen Recalls Every ID.4 SUV in U.S. for Door Malfunction Concerns</a></li>
</ul>
Photo via Shutterstock

Tech

TSLA

Tesla CEO Elon Musk Considers Making Steering Yoke Stationary While Cybertruck Parks Itself

Guardant Health Partners With Agostino Gemelli University Polyclinic Foundation To Launch In-House Liquid Biopsy Testing Service Using Guardant360 CDx At Policlinico Gemelli Facilities In Rome, Italy

<ul>
<li>Phase 2/3 of the DRAGON II trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in approximately 60 adolescent STGD1 subjects across the U.S., U.K., and Japan</li>
<li>Phase 1b of DRAGON II trial to evaluate pharmacokinetics and pharmacodynamics of Tinlarebant in Japanese subjects was recently completed</li>
<li>Tinlarebant granted Orphan Drug and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1</li>
<li>Pivotal global Phase 3 trial of Tinlarebant in GA subjects ("PHOENIX") is ongoing and more than 200 subjects have been enrolled</li>
</ul>

BLTE

Belite Bio Doses First Patient In Phase 2/3 DRAGON II Trial At Tokyo Medical Center For Tinlarebant, An Oral Therapy Targeting STGD1 Retinal Disease; Study To Evaluate Efficacy And Safety In 60 Adolescent Patients Across The U.S., U.K., And Japan

Small Cap Consumer Research analyst Eric Beder reiterates Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) with a Buy and maintains $20 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Lands' End, Maintains $20 Price Target

Guidance

AMSC

AMSC Expects FY24 Revenues Inclusive Of Its NWL Acquisition to Be $50M-$55M, Expects Positive Cash Generation Of $1M-$4M

Telsey Advisory Group analyst Joseph Feldman maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Market Perform and maintains $290 price target.

Telsey Advisory Group Maintains Market Perform on RH, Maintains $290 Price Target

Deutsche Bank analyst Edison Yu reinstates Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Hold and announces $74 price target.

APTV

Deutsche Bank Reinstates Hold on Aptiv, Announces $74 Price Target

Academy Sports Opened One New Store During Q2; Plans To Open A Total Of 15 To 17 Stores In 2024

ELVA

Electrovaya Secures First Purchase Orders From Leading Japanese Construction Equipment Manufacturer

LXRX

Lexicon Pharmaceuticals Announces Phase 3 Trial Results For Sotagliflozin In Insulin-Treated Type 2 Diabetes, Showing Improved Time-In-Range And Glucose Variability; Data To Be Presented At European Association For The Study Of Diabetes Annual Meeting On September 12th

Offerings

PHIN

PHINIA Announces A Proposed Private Offering Of $400,000,000 Of Senior Notes Due 2032

Katapult Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>), an e-commerce-focused financial technology company,&nbsp;has entered a new exclusive agreement with RedPocket Mobile, a leading telecom provider that offers high quality, affordable, and reliable wireless service and mobile devices. Under the terms of the agreement, RedPocket Mobile has integrated Katapult's innovative lease-to-own (LTO) solution into its checkout flow, making Katapult a direct payment option. Katapult's LTO option at checkout is expected to allow more nonprime consumers to access top-tier mobile devices with RedPocket Mobile.

KPLT

Katapult Holdings Enters A New Exclusive Agreement With RedPocket Mobile Integrating Katapult's Lease-To-Own Solution Into Its Checkout Flow, Making Katapult A Direct Payment Option

Academy Sports Projects FY24 Net Sales Of $5.895B-$6.075B Vs. $6.13B Estimate (Prior View: $6.070B-$6.350B); Projects Adjusted EPS Of $5.75-$6.50 Vs. $6.44 Estimate

SMTK

Smartkem Enters Joint Development Agreement With Chip Foundation Semiconductor Technology To Co Develop MicroLED-Based Backlight Technology For Liquid Crystal Displays

Weed Growth Fund

SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEDG#NASDAQ">WEDG</a>) shares are trading lower by roughly 1.16% to $180.52 Monday afternoon. The stock is lower by 24% over the trailing five sessions after the company came out with&nbsp;weak third-quarter&nbsp;guidance.

What Happened With Earnings Last Week?

SolarEdge announced better-than-expected quarterly adjusted earnings of $2.62 per share, surpassing the analyst consensus estimate of $2.55. This represents a marked 175.79% increase compared to earnings of $0.95 per share from the same period last year.

The company also reported quarterly sales of $991.30 million, slightly beating the analyst consensus estimate of $989.17 million by 0.22%. This figure marks a 36.21% increase in sales compared to $727.77 million in the same period last year.

In the third quarter, SolarEdge anticipates revenues ranging from $880 million to $920 million, while the consensus estimate stands at $1.05 billion...<a href="https://www.benzinga.com/news/earnings/23/08/33520387/solaredge-stock-is-spiraling-lower-whats-going-on" target="_blank">Read More</a>

According to data from&nbsp;<a href="https://benzinga.grsm.io/register174" target="_blank">Benzinga Pro</a>, SEDG has a 52-week high of $345.80 and a 52-week low of $178.51.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Weed Growth Fund

News

Latest news for Weed Growth Fund (OTC:WEDG) Stock

Monday, August 07, 2023